新闻

CMS: New Drug Application For Atopic Dermatitis Indication Of Long-Acting Anti-IL-4Rα Humanized Monoclonal Antibody Injection Accepted In China.

31 Oct 2025 09:24

The Marketing Authorization Application has been accepted by National Medical Products Administration on 30 October 2025...

Attachments:

• CMS-NDA_for_AD_Indication_of_Long-acting_Anti-IL-4Ra_Humanized_Monoclonal_Antibody_Injection_Accepted_in_China.pdf

Source: ShareInvestor Express